 |
| |
 | |
Glossary
|
- ACIP
- Advisory Committee on Immunization Practices
- ALT
- alanine aminotransferase
- anti-HAV
- antibody to HAV; indicates acute or resolved infection; indicates a protective immune response to infection or passively acquired antibody or response to vaccination
- anti-HBs
- hepatitis B surface antibody
- anti-HBV
- antibody to hepatitis B virus
- anti-HCV
- antibody to hepatitis C virus
- anti-HDV
- antibody to hepatitis D virus
- anti-HEV
- antibody to hepatitis E virus
- AST
- aspartate aminotransferase
- BUN
- blood urea nitrogen
- CBC
- complete blood count
- CDC
- Centers for Disease Control and Prevention
- CT
- computed tomography
- EBV
- Epstein-Barr virus
- ELISA
- enzyme-linked immunosorbent assay
- ERCP
- endoscopic retrograde cholangiopancreatography
- FDA
- Food and Drug Administration
- G-6-PD
- glucose-6-phosphate dehydrogenase
- HAV
- hepatitis A virus; etiologic agent of hepatitis A; a picornavirus with a single serotype
- HBsAg
- hepatitis B surface antigen
- HBV
- hepatitis B virus
- HCV
- hepatitis C virus
- HDV
- hepatitis D virus
- HIV
- human immunodeficiency virus
- HSV
- herpes simplex virus
- IgG
- immunoglobulin G
- IgG anti-HAV,
- antibody to hepatitis A virus, immunoglobulin G
- IgM
- immunoglobulin M
- IgM anti-HAV
- IgM-class antibody indicating recent infection with HAV
- LDH
- lactic dehydrogenase
- LFT
- liver function test
- N/A
- not applicable
- NSAID
- nonsteroidal anti-inflammatory drug
- RIBA
- recombinant immunoblot assay
- RNA
- ribonucleic acid
- URI
- upper respiratory (tract) infection
Terms
- Anicteric clinical HAV infection
- An illness characterized by fever, myalgia, anorexia, nausea, and other constitutional symptoms without jaundice but with anti-HAV IgM and elevated aminotransferase activity
- Icteric clinical acute hepatitis A
- An illness characterized by fever, myalgia, anorexia, nausea, other constitutional symptoms, jaundice, anti-HAV IgM, and elevated aminotransferase activity
- Inapparent hepatitis A
- An asymptomatic infection in a person whose serum is positive for anti-HAV IgM
- Non-ABCDE hepatitis
- Parenterally transmitted: diagnosis of exclusion, epidemiologic evidence of parenteral or sexual transmission; enterically transmitted: diagnosis of exclusion, epidemiologic evidence of fecal-oral transmission
- Subclinical hepatitis A
- HAV infection in a person without symptoms whose serum is anti-HAV IgM-positive and who has elevated aminotransferase activity
- Total anti-HAV
- IgM and IgG anti-HAV
|
|
|
| Brian J. McMahon, MD, MACP has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Catherine M. Dentinger, FNP, MS has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott. |
|
|
|
The information included herein should never be used as a substitute
for clinical judgment and does not represent an official position of
ACP. Because all PIER modules are updated regularly, printed web pages
or PDFs may rapidly become obsolete. Therefore, PIER users should
compare the date of the last update on the website with any printout
to ensure that the information being referred to is the most current
available.
|
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.
|
|
|
Hepatitis A